Pulmonary pleomorphic carcinoma treated with PD ‐1 inhibitor: Two case reports
Thoracic Cancer · 2023
DOI: 10.1111/1759-7714.15120 ↗Kurz gefasst
Fallbericht in der Zeitschrift Thoracic Cancer, 2023. Verfasst von Tao Jiang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. Hauptthemen laut MEDLINE: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Shanxi Provincial Key Research and Development Project.
Abstract (Originalsprache)
Pulmonary polymorphic carcinoma (PPC) is a rare and poorly differentiated form of non‐small cell lung cancer (NSCLC), accounting for just approximately 0.1% to 0.4% of all NSCLC cases. Historically, the conventional treatments for PPC have been linked to a grim prognosis. However, with the advent of immune checkpoint inhibitors (ICIs), including PD‐1 inhibitors, for the management of NSCLC, our center has witnessed encouraging outcomes in two PPC patients who underwent PD‐1 inhibitor therapy. The first patient was a 70‐year‐old male who initially came to our attention after the discovery of a lung mass during a routine physical examination. A lung biopsy confirmed the diagnosis of PPC, and further complications included brain metastasis. Surgical intervention was conducted for the brain metastases, while PD‐1 inhibitor therapy was employed for the lung tumors. The second patient was a 60‐year‐old male who was admitted with a history of persistent coughing and hemoptysis, which led to the diagnosis of a left lung tumor. Subsequent postoperative pathology revealed pulmonary adenocarcinoma coexisting with PPC. However, 2 months later, distant metastases were detected during a follow‐up examination. The patient encountered difficulty in tolerating the adverse effects of chemotherapy, prompting the initiation of PD‐1 inhibitor treatment. Notably, both patients underwent one cycle of PD‐1 inhibitor therapy without encountering significant adverse reactions, and their responses proved to be promising during re‐examinations. These findings suggest that surgery combined with immunotherapy PD‐1 inhibitor therapy may represent an effective approach for the treatment of PPC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thoracic Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
- Department of Pathology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
ORCID-Profile: Yong Zhang, Guangjian Zhang, Qifei Wu
Förderung
- National Natural Science Foundation of China
- Shanxi Provincial Key Research and Development Project
Zitieren
APA
Jiang, T., Wang, H., Xue, F., Wu, X., Ni, M., Wang, Y., Chen, N., Zhang, Y., Zhang, G., Fu, J., Liu, X., & Wu, Q. (2023). Pulmonary pleomorphic carcinoma treated with PD ‐1 inhibitor: Two case reports. Thoracic Cancer. https://doi.org/10.1111/1759-7714.15120
Vancouver
Jiang T, Wang H, Xue F, Wu X, Ni M, Wang Y, et al. Pulmonary pleomorphic carcinoma treated with PD ‐1 inhibitor: Two case reports. Thoracic Cancer. 2023. doi:10.1111/1759-7714.15120
BibTeX
@article{Jiang2023,
author = {Jiang, Tao and Wang, Hao and Xue, Fei and Wu, Xuanpeng and Ni, Ming and Wang, Yuanyuan and Chen, Nanzheng and Zhang, Yong and Zhang, Guangjian and Fu, Junke and Liu, Xi and Wu, Qifei},
title = {Pulmonary pleomorphic carcinoma treated with PD ‐1 inhibitor: Two case reports},
journal = {Thoracic Cancer},
year = {2023},
doi = {10.1111/1759-7714.15120}
}
EUVIMED